About COBRE CCRD

The mission of COBRE Center for Cancer Research Development at Rhode Island Hospital is to create, interpret and apply new knowledge based on original, collaborative, multidisciplinary laboratory studies of the cellular and molecular pathways leading to carcinoma.

Such knowledge will be generated in an environment that fosters career development of promising junior investigators and employs cutting-edge methodology and applications to further our understanding of the cancer process. Basic knowledge gained will be used to design and implement novel diagnostic and treatment protocols benefiting patients in the Lifespan Cancer Institute and the community at large.

COBRE CCRD Activities

The proteomics core continues to provide the latest technologies and methodologies for analyzing changes in the protein expression profiles that occur when normal cells become cancerous. The goal is to find new markers for early detection and diagnosis. Proteomics continues to collaborate in the development of new applications for a recently acquired imaging mass spectrometer, applications that we expect to provide new strategies for biomarker discovery and new diagnostic tools for the clinician.

This website was made possible by NIH Grant Number RR-P20 RR17695 from the Institutional Development Award (IDeA) Program of the National Center for Research Resources/Center of Biological Research Excellence (COBRE).

In 2002, Rhode Island Hospital received an $8.2 million grant from the National Institutes of Health Centers of Biomedical Research Excellence (COBRE) to establish the COBRE Center for Cancer Research Development at Rhode Island Hospital (COBRE CCRD).

In July 2009, the CCRD received a five-year renewal of $11.2 million in total funding to continue the development of the cancer research effort at Rhode Island Hospital. During the next five years the Center for Cancer Research Development continues to move forward with its mission to create, interpret and apply new knowledge based on original, collaborative, multidisciplinary laboratory studies to uncover the cellular and molecular pathways leading to cancer arising in the liver, intestine, pancreas and colon. The acquisition of such knowledge will be facilitated by creating an environment that fosters career development of promising investigators and provide state-of-the-art technologies required for cutting-edge research. Basic knowledge gained will be used to design and implement novel diagnostic and treatment protocols benefiting patients in the Lifespan Cancer Institute and the community at large.